Investigators demonstrated that serine/threonine/tyrosine kinase 1 (STYK1) directly binds to β-catenin and GSK3β, inhibiting GSK3β activity by increasing the level of its kinase-inactive form, which is phosphorylated at S9, and promoting its sequestration into multivesicular bodies.
[Signal Transduction and Targeted Therapy]